After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...
Investor's Business Daily on MSN
Why these four biotech stocks prove that follow-on entries still pop up in stock market leaders
AnaptysBio recorded $234 million in sales over the past four quarters.
Odyssey Therapeutics secured a valuation of $899.9 million after its shares rose 11.1% in their Nasdaq debut on Friday, ...
Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout ...
Now, it’s worth noting Stock Advisor’s total average return is 963% — a market-crushing outperformance compared to 201% for ...
Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...
May 7 (Reuters) - Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results